Sirna Therapeutics

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration

Retrieved on: 
Wednesday, November 29, 2023
Seniors, Biotechnology, Pharmaceutical, Optical, Health, Genetics, Consumer, Clinical Trials, Intravitreal injection, Safety, Neovascularization, Visual acuity, RNA interference, Homeostasis, Vance DeGeneres, Patient, Small RNA, DLT, Therapy, RNA, Harvard Medical School, AMD, Macular degeneration, Sirna Therapeutics, KOSDAQ, Quality of life, Paratriathlon, Inflammation, Optimism, Pharmaceutical industry

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).
  • This phase 1 study is a multi-center, single-dose, dose-escalating study to evaluate the safety and tolerability of OLX10212 in patients with neovascular AMD.
  • The primary endpoints of this study were safety and tolerability assessments associated with each intravitreal OLX10212 injection.
  • The safety and tolerability evaluations, together with preliminary BCVA improvement of OLX10212 encourage further development of OLX10212 for AMD.

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Retrieved on: 
Friday, December 15, 2023
Principal, Drug development, MIT, Sirna Therapeutics, Organic chemistry, CSO, Morgenthaler, Culture, McGill University, Series, Therapy, University, Corporate title, Growth, AI, Pharmaceutical industry, Sanofi, Merck, Ioan Totu

"He brings exceptional experience and acumen to a company poised to bring much-needed therapies to market.

Key Points: 
  • "He brings exceptional experience and acumen to a company poised to bring much-needed therapies to market.
  • His strong management experience will help shape Totus as we continue to advance breakthrough therapeutics, and just as importantly, Nassim embodies our culture and values."
  • Before joining Totus Medicines, Dr. Usman served as President, CEO and Board member at Catalyst Biosciences (NASDAQ:CBIO, now Gyre Therapeutics, NASDAQ:GYRE).
  • Proceeds from the Series B financing will be used to advance Totus' clinical program, expand the pipeline, and evolve the platform.

Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Disease

Retrieved on: 
Wednesday, October 25, 2023
Research, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Glycogen storage disease type II, Biomarker, Glycogen, Protalix BioTherapeutics, MD, Liver, Doctor of Philosophy, Pharmacokinetics, Tissue, Sirna Therapeutics, Safety, Patient, Pharmaceutical industry

ABX1100 is a first-in-class molecule representing a new approach to reducing toxic levels of glycogen that build up in muscles of patients with Pompe Disease.

Key Points: 
  • ABX1100 is a first-in-class molecule representing a new approach to reducing toxic levels of glycogen that build up in muscles of patients with Pompe Disease.
  • “We are thrilled to advance ABX1100 into the clinic,” said Mittie Doyle, MD, FACR, Chief Medical Officer of Aro Biotherapeutics.
  • The study is designed to assess safety, tolerability, pharmacokinetics along with various pharmacodynamic biomarkers that will be evaluated to demonstrate target engagement.
  • The company anticipates presenting data from the Phase 1 study in 2024.

Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program

Retrieved on: 
Wednesday, October 25, 2023
CAR, Central Waqf Council, Patent, Autoimmunity, CD19, OTC, Sirna Therapeutics, Quicc!, NR2F6, SAN, Vaccine

SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-exp...) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs....

Key Points: 
  • The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments.
  • These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA.
  • NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.
  • "Having a second confirmatory study gives us confidence we are making the right decision to pursue these novel cell therapies focused on autoimmunity," says Dr. David Koos, Chairman and CEO of the company.

Regen BioPharma, Inc. Expects Second Phase of Confirmatory Study Shortly

Retrieved on: 
Wednesday, October 18, 2023
Quicc!, CAR, Cancer, Sirna Therapeutics, Messenger, NR2F6, Real-time, SAN, Vaccine

SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells.

Key Points: 
  • SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells.
  • The Company has recently received unexpected and potentially extremely useful data from one of its contract research organizations (CRO) retained to perform experimental studies on the Company's DuraCAR CAR T-cell therapeutic.
  • These studies demonstrated that T cells which express the chimeric antigen receptor (CAR) construct expressing siRNA for NR2F6 can be successfully created.
  • "A second unrelated CRO is currently performing qRT-PCR tests to determine if NR2F6 mRNA is elevated or inhibited by our  CAR in T-Cells," says Dr. Harry Lander, Chief Scientific Consultant to the Company."

Regen BioPharma, Inc. Receives First Phase of Confirmatory Study

Retrieved on: 
Tuesday, October 10, 2023
Sirna Therapeutics, OTC, Autoimmunity, Cell, Data, Cancer, Quicc!, CAR, SAN, CD19, Small RNA, Messenger, NR2F6, Vaccine

SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-exp...) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs....

Key Points: 
  • The company has now received the first set of confirmatory data which demonstrates that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 were  successfully created.
  • In addition, the siRNA that is designed into the CAR T-cell was very highly expressed.
  • Subsequent studies will determine if the expression of NR2F6 mRNA is suppressed or enhanced as a result of the high expression of siRNA.
  • If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors.

Studies On Regen BioPharma, Inc.'s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory Studies

Retrieved on: 
Tuesday, September 19, 2023
Quicc!, Sirna Therapeutics, CAR, CD19, SAN, NR2F6, Autoimmunity, OTC, Vaccine

SAN DIEGO, Sept. 19, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) had previously discussed initiation of a series of experiments to validate its DuraCAR CAR-T cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-exp...). 

Key Points: 
  • The first phase of in vitro experiments successfully synthesized and expressed in transfected cells the chimeric antigen receptor (CAR) construct targeting CD19 and NR2F6.
  • However, a second set of experiments yielded unexpected results whereby siRNAs designed to suppress NR2F6 mRNA expression yielded the opposite result.
  • The company has engaged a contract research organization (CRO) that is independent of the CRO which performed the second set of experiments to determine if these surprising findings are reproducible.
  • If confirmed, these results could lead to the development of a therapy whereby T-Cells that suppress autoimmunity can be created.

CyGenica Limited Secures USFDA Approval for Orphan Drug Designation for Novel Drug Conjugate in Glioblastoma Multiforme Treatment

Retrieved on: 
Tuesday, September 12, 2023
Sirna Therapeutics, Therapy, GBM, USFDA, Cancer, Hope, Glioblastoma, Brain, Patient, Rare, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

Dr. Nusrat J M Sanghamitra, Co-founder and CEO of CyGenica, revealed that the U.S. Food and Drug Administration (USFDA) has granted Orphan Drug Designation for their revolutionary drug conjugate for the treatment of GBM.

Key Points: 
  • Dr. Nusrat J M Sanghamitra, Co-founder and CEO of CyGenica, revealed that the U.S. Food and Drug Administration (USFDA) has granted Orphan Drug Designation for their revolutionary drug conjugate for the treatment of GBM.
  • CyGenica's Orphan Drug Designation approval for their novel drug conjugate demonstrates a resolute commitment to address the unmet medical needs of GBM patients.
  • Dr. Nusrat J M Sanghamitra stated, "We are incredibly thrilled to receive the USFDA's approval for our Orphan Drug Designation for our novel drug conjugate in GBM treatment.
  • As CyGenica continues to advance their novel drug conjugate and GEENIE platform, the company is eager to collaborate with biotech investors and pharmaceutical companies.

Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers

Retrieved on: 
Tuesday, August 15, 2023
Asos, Arena Pharmaceuticals, Gene editing, Cancer, RNA, TPN, Doctor of Philosophy, Patient, Platform, SAN, Extracellular matrix, Drug discovery, Rhône-Poulenc, Sirna Therapeutics, Therapy, Messenger, Pharmacology, Ionis Pharmaceuticals, Disease, Vaccine, Ionis, MD, Sanofi

SAN DIEGO, Aug. 15, 2023 /PRNewswire/ -- Impilo Therapeutics, Inc. ("Impilo"), a privately held drug discovery and development company, today announced that it has launched with the mission to enable nucleic acid-based medicines to effectively treat solid tumor cancers.

Key Points: 
  • SAN DIEGO, Aug. 15, 2023 /PRNewswire/ -- Impilo Therapeutics, Inc. ("Impilo"), a privately held drug discovery and development company, today announced that it has launched with the mission to enable nucleic acid-based medicines to effectively treat solid tumor cancers.
  • The Company's technology is derived from an agreement with Lisata Therapeutics, Inc. (NASDAQ: LSTA) ("Lisata") for the targeted delivery of nucleic acid-based medicines.
  • Nucleic acid-based medicines have been approved for a range of diseases, but none for the treatment of cancer.
  • The tumor stroma, composed of non-cancerous cells and extracellular matrix surrounding cancer cells, is a primary impediment to effective drug delivery to treat solid tumor cancers and a particular challenge for nucleic acid-based drugs.